10 completed, 2 active not recruiting, 2 recruiting. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 10, Active not recruiting 2, Recruiting 2 |
Follow Turner Syndrome: new trials by email Literature Review of Turner Syndrome trials Research Report on Turner Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature Inpegsomatropin-Injection, Givopegsomatropin Solution Injection - Turner Syndrome | Phase 3 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 84 | 2026-07-05 | 2026-07-22 |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector - Turner Syndrome, Short Stature Homeobox Gene Mutation | Phase 3 | Recruiting | Ascendis Pharma A/S | 186 | 2025-12-12 | 2026-11-05 |
| A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Somapacitan - SGA, Turner Syndrome | Phase 3 | Active not recruiting | Novo Nordisk A/S | 47 | 2023-02-01 | 2026-08-13 |
| A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS | Phase 3 | Active not recruiting | Novo Nordisk A/S | 412 | 2022-08-10 | 2026-06-12 |
| A Clinical Study to Assess the Efficacy and Safety of DA-3002 DA-3002, Genotropin® - Turner's Syndrome | Phase 3 | Completed | Dong-A ST Co., Ltd. | 58 | 2013-02-01 | 2018-07-26 |
| An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG ZOMACTON - Turner's Syndrome | Phase 3 | Completed | Ferring Pharmaceuticals | 27 | 2005-10-01 | 2011-05-20 |
| Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Somatropin (rDNA origin) - Turner Syndrome, Renal Insufficiency, Chronic | Phase 3 | Completed | Ipsen | 251 | 2004-06-01 | 2019-12-09 |
| Estrogen Treatment (Oral vs. Patches) in Turner Syndrome 17 beta estradiol - Turner Syndrome, Hypogonadism | Phase 3 | Completed | Nemours Children's Clinic | 16 | 2001-01-01 | 2017-11-30 |
| Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 3 | Completed | Novo Nordisk A/S | 168 | 2000-10-23 | 2017-02-27 |
| The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Somatropin - Turner Syndrome | Phase 3 | Completed | Eli Lilly and Company | 100 | 1999-08-01 | 2006-12-04 |
| Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome 17-beta estradiol - Genetic Disorder, Turner Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 50 | 1998-07-23 | 2017-02-28 |
| The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome estrogen, androgen, placebo - Turner Syndrome | Phase 3 | Completed | Thomas Jefferson University | 200 | 1992-11-01 | 2012-06-05 |
| Somatropin Treatment to Final Height in Turner Syndrome Somatropin, Ethinyl estradiol, Medroxyprogesterone acetate - Turner Syndrome | Phase 3 | Completed | Eli Lilly and Company | 154 | 1989-02-01 | 2010-01-27 |
| Use of Somatropin in Turner Syndrome somatropin - Genetic Disorder, Turner Syndrome | Phase 3 | Completed | Novo Nordisk A/S | 57 | 1987-09-14 | 2017-02-28 |
Dwarfism (4) · Genetic Diseases, Inborn (3) · Noonan Syndrome (3) · Failure to Thrive (2) · Chromosome Disorders (1) · Endocrine System Diseases (1) · Hypogonadism (1) · Pituitary Diseases (1) · Primary Ovarian Insufficiency (1) · Renal Insufficiency, Chronic (1) · Sex Chromosome Disorders (1) · Sex Chromosome Disorders of Sex Development (1) · Syndrome (1)
Cardiovascular Abnormalities (14) · Cardiovascular Diseases (14) · Congenital Abnormalities (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Disorders of Sex Development (14) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Gonadal Disorders (14) · Gonadal Dysgenesis (14) · Heart Defects, Congenital (14) · Heart Diseases (14) · Male Urogenital Diseases (14) · Urogenital Abnormalities (14) · Urogenital Diseases (14) · Chromosome Disorders (13)
Human Growth Hormone (7) · Estradiol (2) · Growth Hormone (2) · somapacitan (2) · Androgens (1) · Estrogens (1) · Ethinyl Estradiol (1) · Medroxyprogesterone Acetate (1) · lonapegsomatropin (1)
Novo Nordisk A/S (5) · Eli Lilly and Company (2) · Ascendis Pharma A/S (1) · Dong-A ST Co., Ltd. (1) · Ferring Pharmaceuticals (1) · Ipsen (1) · Nemours Children's Clinic (1) · Thomas Jefferson University (1) · Xiamen Amoytop Biotech Co., Ltd. (1)
United States (6) · Spain (5) · France (4) · South Korea (4) · Germany (3) · Italy (3) · Netherlands (3) · United Kingdom (3) · Belgium (2) · Canada (2) · China (2) · Czechia (2) · Finland (2) · Greece (2) · Israel (2)
Byung Kyu Suh, M.D., Ph.D. (1) · Chang Jong Kim, M.D., Ph.D. (1) · Cheol Woo Ko, M.D., Ph.D. (1) · Choong Ho Shin, M.D., Ph.D. (1) · Dong Kyu Jin, M.D.,Ph.D. (1) · Han Wook Yoo, M.D., Ph.D. (1) · Heon Suk Han, M.D., Ph.D. (1) · Ho Seong Kim, M.D., Ph.D. (1)
PMID 15784709, PMID 16757526, PMID 20733274, PMID 21619701, PMID 34893062, PMID 41712606, PMID 41774755
2004 (1)